Advances in understanding the peptide neurotransmitter NAAG and appearance of a new member of the NAAG neuropeptide family
about
In vivo assessment of neurotransmitters and modulators with magnetic resonance spectroscopy: application to schizophreniaThe Immune Syntax Revisited: Opening New Windows on Language EvolutionNAAG peptidase inhibition in the periaqueductal gray and rostral ventromedial medulla reduces flinching in the formalin model of inflammationNAAG peptidase inhibitors block cognitive deficit induced by MK-801 and motor activation induced by d-amphetamine in animal models of schizophrenia.Inhibition of glutamate carboxypeptidase II (GCPII) activity as a treatment for cognitive impairment in multiple sclerosis.Metabolism changes during aging in the hippocampus and striatum of glud1 (glutamate dehydrogenase 1) transgenic mice.Pharmacokinetics and pharmacodynamics of the glutamate carboxypeptidase II inhibitor 2-MPPA show prolonged alleviation of neuropathic pain through an indirect mechanism.Functional up-regulation of endopeptidase neurolysin during post-acute and early recovery phases of experimental stroke in mouse brain.Amino acid- vs. peptide-odorants: responses of individual olfactory receptor neurons in an aquatic species.Growth hormone-releasing hormone effects on brain γ-aminobutyric acid levels in mild cognitive impairment and healthy aging.Lactoferrin during lactation protects the immature hypoxic-ischemic rat brain.Glutamate carboxypeptidase II gene knockout attenuates oxidative stress and cortical apoptosis after traumatic brain injury.ATP-binding Cassette Subfamily C Member 5 (ABCC5) Functions as an Efflux Transporter of Glutamate Conjugates and Analogs.Reversible disulfide formation of the glutamate carboxypeptidase II inhibitor E2072 results in prolonged systemic exposures in vivo.Immunohistological and electrophysiological evidence that N-acetylaspartylglutamate is a co-transmitter at the vertebrate neuromuscular junctionNAAG peptidase inhibitors and deletion of NAAG peptidase gene enhance memory in novel object recognition test.N-acetylaspartate (NAA) and N-acetylaspartylglutamate (NAAG) promote growth and inhibit differentiation of glioma stem-like cellsSuppressing N-Acetyl-l-Aspartate Synthesis Prevents Loss of Neurons in a Murine Model of Canavan LeukodystrophyAre amyloid-degrading enzymes viable therapeutic targets in Alzheimer's disease?NAAG, NMDA receptor and psychosisBlockade of N-acetylaspartylglutamate peptidases: a novel protective strategy for brain injuries and neurological disorders.Adapting brain metabolism to myelination and long-range signal transduction.The therapeutic and diagnostic potential of the prostate specific membrane antigen/glutamate carboxypeptidase II (PSMA/GCPII) in cancer and neurological diseaseN-acetylaspartylglutamate is an agonist at mGluR₃ in vivo and in vitro.Nociception modulation by supraspinal group III metabotropic glutamate receptors.A role for the locus coeruleus in the analgesic efficacy of N-acetylaspartylglutamate peptidase (GCPII) inhibitors ZJ43 and 2-PMPA.NAAG Peptidase Inhibitors Act via mGluR3: Animal Models of Memory, Alzheimer's, and Ethanol Intoxication.mGluR2 versus mGluR3 Metabotropic Glutamate Receptors in Primate Dorsolateral Prefrontal Cortex: Postsynaptic mGluR3 Strengthen Working Memory Networks.Mice lacking glutamate carboxypeptidase II develop normally, but are less susceptible to traumatic brain injury.Striatal N-acetylaspartate synthetase Shati/Nat8l regulates depression-like behaviors via mGluR3-mediated serotonergic suppression in mice.Overexpression of Shati/Nat8l, an N-acetyltransferase, in the nucleus accumbens attenuates the response to methamphetamine via activation of group II mGluRs in mice.Local enema treatment to inhibit FOLH1/GCPII as a novel therapy for inflammatory bowel disease.Vesicular uptake of N-acetylaspartylglutamate is catalysed by sialin (SLC17A5).Behavioral impairment in SHATI/NAT8L knockout mice via dysfunction of myelination development.Immuno-pharmacological characterization of group II metabotropic glutamate receptors controlling glutamate exocytosis in mouse cortex and spinal cord.Glutamatergic and Neuronal Dysfunction in Gray and White Matter: A Spectroscopic Imaging Study in a Large Schizophrenia Sample.Brain Nat8l Knockdown Suppresses Spongiform Leukodystrophy in an Aspartoacylase-Deficient Canavan Disease Mouse Model.Unique Molecular Regulation of Higher-Order Prefrontal Cortical Circuits: Insights into the Neurobiology of Schizophrenia.
P2860
Q28083121-91B5978D-F75F-4CDB-B36C-54CB854774F3Q28602830-5EC59610-907D-426E-A132-0529F4372BCFQ30459203-BDECF2F4-5A05-4B71-B001-A985E37CC57DQ30465008-25517864-57CA-4834-8692-367206939FF2Q30530185-1DF6E896-9369-4824-AD4E-A5FB23B64904Q33893780-C50ED4AA-A3C1-41F0-AF2A-417C2D8770D7Q34293335-88B4175D-626E-4C3C-9075-011A6D7F0CC1Q34380550-5385961A-6CAC-4808-A5AE-6DC02D7CC21FQ34541653-60DB664C-7997-456C-9E71-3EC9A6A18633Q34652032-7FE5BD77-9EE6-4F7A-A41C-DC617D62B7E4Q34824724-CEB96CAF-2778-4A8F-ABFA-82E5A9328D82Q35993112-A3B9DA3F-DCE9-4289-8EE9-8230E8E59397Q36381928-42728330-FC31-42BF-85A0-CABD82376A07Q36406289-849B1DB7-2C71-4D49-AC47-7F41102BB587Q36514196-7412F195-5600-4308-B64F-777922098289Q36675499-F64EC6AB-2F71-43EC-9447-6B7B9635C7B3Q37151094-A6CB7956-D52A-47ED-8F72-1617B5BB16F8Q37592141-FEF61653-BDA6-45C2-84AF-F96C9837CCD3Q37961852-E5C60EA9-85DA-4709-B44F-D1E11D3E6FC1Q37981289-EA59F14D-4E28-4466-BE48-4E728B724154Q38185090-7C956888-E4AA-4E89-BBD8-B931DE290222Q38240551-12184356-4FBD-454E-BEA1-FCA39B9D8A8DQ38831232-FB822392-0B93-4D08-9705-902CEF1A5146Q38833017-8226AF03-1295-49ED-8E75-B998F8706B7CQ38882060-A38CDCD2-6138-4D62-938E-B0307DF307FFQ38887993-90EDF997-3826-4CBC-90C2-2E0DCE286C99Q38912835-8C62DD5C-56CC-47A3-ADE8-1296BBB8ED50Q39008914-DAC30D12-5B6C-453F-BE7E-A95361F944C0Q41074666-6D26A522-98C0-41B1-8E6C-7DE1312129BDQ41918980-FCC37FEA-0214-41C0-80FA-08A221405962Q42235808-02BA2D70-4CAF-43F8-B639-8B63106904ABQ42602745-1FE568C9-1A5B-46C6-BA7D-D5CB20911F3AQ44954480-1F52DC85-7C4D-48BD-BAFB-C874AAEC42DFQ47140253-94DB179F-6842-429C-B866-9995D8207BAEQ47717335-9A1A346A-7308-428D-9A11-0FE6DD33B792Q48557473-5DA70B69-F2E4-44C5-B728-ADA66CD23663Q49886923-34AC103B-D912-4DF9-AB17-27AF9CFE1B4EQ50535284-CDDC800C-17E1-49E6-873E-D76A3856942F
P2860
Advances in understanding the peptide neurotransmitter NAAG and appearance of a new member of the NAAG neuropeptide family
description
2011 nî lūn-bûn
@nan
2011 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Advances in understanding the ...... f the NAAG neuropeptide family
@ast
Advances in understanding the ...... f the NAAG neuropeptide family
@en
type
label
Advances in understanding the ...... f the NAAG neuropeptide family
@ast
Advances in understanding the ...... f the NAAG neuropeptide family
@en
prefLabel
Advances in understanding the ...... f the NAAG neuropeptide family
@ast
Advances in understanding the ...... f the NAAG neuropeptide family
@en
P2093
P2860
P1476
Advances in understanding the ...... f the NAAG neuropeptide family
@en
P2093
Caterina P Profaci
Daiying Zuo
John C Madore
Joseph H Neale
Kaleen M Lavin
Karolina J Janczura
Rafal T Olszewski
Tomasz Bzdega
P2860
P304
P356
10.1111/J.1471-4159.2011.07338.X
P407
P577
2011-07-01T00:00:00Z